Bharat Parenterals Limited has filed its annual report for the financial year 2025-26 with the Bombay Stock Exchange. The filing was made on August 27, 2026, pursuant to Regulation 34(1)(a) of the SEBI Listing Regulations.

Annual Report Filing and AGM Notice

The company submitted the document to the Corporate Relations Department at BSE Limited. The annual report includes the notice for the 33rd Annual General Meeting (AGM), which is scheduled to be held on Saturday, September 19, 2026. The meeting will be conducted through Video Conferencing or Other Audio-Visual Means.

The annual report is also available on the company’s website at www.bplindia.in . Sharmin Soni, the Company Secretary and Compliance Officer, signed the communication dated August 27, 2026.

Record Date and Dividend Eligibility

Shareholders whose names appear in the books as Beneficial Owners as at the close of business hours on September 12, 2026, will be entitled to receive the dividend. This date also serves as the cut-off for ascertaining the names of members eligible to cast their votes electronically in respect of the businesses to be transacted at the AGM.

The company has issued this intimation pursuant to Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investors are urged to ensure their KYC details, including PAN and bank account information, are updated with their Depository Participants to avoid any issues with dividend processing or folio freezing. Members holding shares in physical form are requested to consider dematerializing their holdings to ensure compliance with SEBI guidelines and to facilitate faster and safer transactions.

AGM Details and Logistics

The 33rd AGM will commence at 11:00 am on September 19, 2026. The meeting will be conducted through Video Conferencing or Other Audio-Visual Means, in compliance with applicable regulatory circulars. The venue of the meeting shall be deemed to be the Registered Office of the company at Survey No. 144-A, Jarod-Samlaya Road, Vill. Haripura, Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Shareholders can attend the proceedings via an electronic platform. The notice of the AGM, along with the Annual Report for FY25-26, will be dispatched electronically to members who have registered their email addresses with the company or their Depository Participants.

In accordance with Regulation 36(1)(b) of the SEBI Listing Regulations, the company has dispatched a letter to those members whose email addresses are not registered. The letter provides a web-link to access the Annual Report and the AGM Notice. These documents are also available on the company’s website at www.bplindia.in under Home → Investors → Annual Report → 2025-26.

Members holding shares in physical form or those who have not registered their email addresses are advised to update their details to receive the documents and login credentials for e-voting. The company has engaged NSDL as the authorized agency to facilitate remote e-voting and voting during the meeting.

E-Voting Process

Pursuant to Section 108 of the Companies Act, 2013, and SEBI Listing Regulations, members will have the opportunity to cast their votes using remote e-voting or the e-voting system available during the AGM. Detailed instructions for joining the meeting and casting votes will be provided in the official notice of the AGM.

For queries, members may contact the Registrar and Transfer Agent, Adroit Corporate Services Private Limited, at info@adroitcorporate.com . Forms for nomination and KYC updation are available on the company website.

Bharat Parenterals Limited equity shares have been permitted to trade and admitted to dealings on the National Stock Exchange of India Limited (NSE). The trading commenced on August 17, 2026, under the Permitted to Trade category in the Capital Market Segment.

The company disclosed the development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was issued on August 20, 2026, by Sharmin Nareshkumar Soni, Company Secretary & Compliance Officer.

Listing Details

The NSE notified its members of the admission via Circular No. NSE/CML/75748 dated August 14, 2026. The circular specified the security codes and lot sizes for trading purposes.

Regulatory Context

The admission aligns with Regulation 3.1.1 of the National Stock Exchange (Capital Market) Trading Regulations Part A. Trading in the securities is identified by the designated code BPLPHARMA. The market lot size for the securities is fixed at 1.

Bharat Parenterals Limited was already listed on the Bombay Stock Exchange. The NSE listing adds a secondary exchange platform for its equity shares. The company operates from Vadodara, Gujarat, and holds WHO-GMP certification.